全球器官移植诊断市场－按产品、应用、移植类型、技术、最终用户、地区和竞争格局分類的产业规模、份额、趋势、机会和预测（2021-2031 年）

全球器官移植诊断市场预计将从 2025 年的 64.7 亿美元成长到 2031 年的 98.7 亿美元，复合年增长率为 7.29%。

该市场涵盖了组织配型、病原体筛检和移植过程中免疫监测所必需的各种检测方法、试剂和仪器系统。推动这一增长的主要因素是全球慢性疾病导致器官衰竭的趋势日益加剧，以及人口老化需要更先进的医疗干预，这些因素共同推动了对严格的相容性分析的需求。全球捐赠与移植观察站的报告也印证了这个日益增长的临床需求：到2024年12月，全球固态器官移植数量将达到172,397例，比上一个评估週期增加9.5%。

儘管该领域呈现积极的成长趋势，但由于全球捐赠器官长期短缺，仍面临严峻的挑战。庞大的患者等待名单与可用器官的供不应求之间的不平衡限制了手术数量，从而限制了术前交叉配对试验配型和确诊诊断的潜在市场规模。此外，分子检测技术的高成本，以及新兴经济体报销政策的不一致性，进一步阻碍了这些重要诊断方案的广泛应用和推广。

市场驱动因素

对非侵入性移植后监测日益增长的需求正在改变全球器官移植诊断市场，为病患监测和移植器官保护树立了新的标准。医疗专业人员越来越多地采用液态切片解决方案，该方案可检测供体来源的游离DNA (dd-cfDNA)。与传统的组织切片检查相比，dd-cfDNA能够更快、更灵敏地检测出排斥反应的征兆，从而减轻患者负担并提高免疫监测的准确性。这种转变正推动诊断服务提供者的检测量显着成长。例如，CareDx在其2025年11月发布的「2025年第三季财务业绩」报告中指出，其提供的检测服务数量达到50,300项，年成长13%，证实了这些先进方法在临床应用中的快速普及。

同时，导致器官衰竭的慢性疾病日益增多，是推动移植前相容性检测持续扩展的主要因素。由于末期肾功能衰竭和心血管衰竭等疾病导致等待移植的患者人数不断增加，严格的组织相容性分析和HLA型检测对于确保器官的合理分配至关重要。根据美国卫生资源与服务管理局 (HRSA) OrganDonor.gov 网站 2025 年 5 月更新的数据，全国器官移植等待名单上的患者人数已超过 10.3 万人。如此强劲的临床需求支撑着手术能力。器官捐赠和移植网络 (OPTN) 2025 年 1 月的报告显示，2024 年美国器官移植数量达到创纪录的 48,149 例，凸显了该体系对健全诊断基础设施的依赖。

市场挑战

供体器官持续短缺是限制全球器官移植诊断市场商业性成长的主要因素。由于诊断测试的使用与手术数量密切相关，器官供应有限实际上限制了市场的收入潜力。这种限制降低了术前相容性检测的频率，并限制了能够进入移植后监测阶段的患者数量。因此，该行业无法完全满足临床需求，而由于供体器官供应停滞不前，可供移植的患者数量也受到实际限制。

这种结构性瓶颈正在扩大潜在需求与实际检测量之间的差距。根据器官取得和移植网络的数据，截至2024年，美国国家器官移植等待名单上已有超过10.3万人。这一巨大缺口表明，捐赠者短缺如何阻碍了很大一部分患者获得全面的诊断服务，从而妨碍了原本可以透过常规检测获得的可持续收入来源的建立。

市场趋势

人工智慧 (AI) 和机器学习 (ML) 的应用正在革新预测性风险分层，旨在解决传统方法无法应对的器官获取效率低下问题。这些先进技术能够解读复杂的供体变量，优化从终止生命维持到器官摘取这一关键决策视窗。能够准确预测捐赠者预后的 AI 工具可最大限度地减少可用器官的浪费，从而直接缓解持续存在的供不应求。例如，《卫报》在 2025 年 11 月报道称，史丹佛大学研究人员开发的一种机器学习模型与标准预测相比，可将器官试验的浪费减少 60%。

同时，随着新型RNA生物标记的引入，市场正朝着个人化移植医学的方向发展，这些生物标记能够提供比标准液态生物检体更深入的资讯。临床医生越来越依赖转录组分析来更特异性评估排斥风险，从而实现免疫抑制疗法的个人化定制，并降低长期移植毒性。这种向精准诊断的转变也体现在下一代检测技术的商业性成功上；Verisi Diex在其2025年7月发布的《企业趋势报告》中宣布，其诊断测试Tutivia在2025年第二季度已获得299份订单，这表明人们越来越依赖先进的基因组特征来进行个性化患者管理。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球器官移植诊断市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 透过提供（试剂盒和检测方法、耗材、服务）
  • 按应用（供体检测（移植前检测：组织相容性检测、血液分析检测及其他检测；移植后检测：感染后检测、疾病风险检测及其他检测），受器检测（移植前检测：组织相容性检测、血液分析检测及其他检测；移植后检测：感染后检测、疾病风险检测及其他检测））
  • 依移植类型（固态器官移植（肾臟、肝臟、肺臟、胰臟、其他器官移植）、干细胞移植）
  • 依技术分类（分子技术（PCR、Sanger测序、次世代定序（NGS）、其他分子技术）、非分子技术（血清学、流式细胞技术）、其他技术）
  • 依最终使用者划分（医院/移植中心、学术/研究机构、参考实验室、其他最终使用者）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美器官移植诊断市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

7. 欧洲器官移植诊断市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区器官移植诊断市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲器官移植诊断市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章 南美洲器官移植诊断市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球器官移植诊断市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Thermo Fisher Scientific, Inc.
• Illumina, Inc.
• F. Hoffmann La-Roche Ltd
• Abbott
• QIAGEN
• Bruker
• Becton, Dickinson and Company
• Immucor, Inc.
• Bio-Rad Laboratories, Inc.
• Omixon Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Organ Transplant Diagnostics Market is projected to expand from USD 6.47 Billion in 2025 to USD 9.87 Billion by 2031, reflecting a compound annual growth rate of 7.29%. This market encompasses a broad range of assays, reagents, and instrument systems essential for histocompatibility testing, pathogen screening, and immune monitoring throughout the transplant continuum. The primary catalysts for this growth are the increasing global prevalence of chronic diseases causing organ failure and an aging population requiring advanced medical interventions, which collectively drive the demand for rigorous compatibility profiling. As evidence of this rising clinical need, the Global Observatory on Donation and Transplantation reported in December 2024 that global solid organ transplant volumes reached 172,397 procedures, marking a 9.5% increase over the prior assessment cycle.

Despite the positive growth trajectory, the sector encounters significant hurdles stemming from the chronic global shortage of donor organs. This imbalance between the extensive waitlists of patients and the scarce supply of viable organs limits the number of surgeries performed, thereby placing a ceiling on the addressable market for pre-surgical cross-matching and confirmatory diagnostics. Additionally, the high costs associated with molecular testing technologies, combined with inconsistent reimbursement policies in emerging economies, pose further barriers that may hinder the widespread accessibility and expansion of these essential diagnostic solutions.

Market Driver

The escalating demand for non-invasive post-transplant monitoring is transforming the Global Organ Transplant Diagnostics Market by setting new benchmarks for patient surveillance and allograft protection. Medical professionals are increasingly utilizing liquid biopsy solutions that detect donor-derived cell-free DNA (dd-cfDNA) to spot potential rejection events with greater speed and sensitivity than traditional tissue biopsies, reducing patient burden while enhancing immune monitoring accuracy. This shift is driving significant volume growth for diagnostic providers; for instance, CareDx reported in its 'Third Quarter 2025 Financial Results' in November 2025 that testing services volume reached 50,300 tests, a 13% increase from the previous year, underscoring the rapid clinical adoption of these advanced modalities.

Concurrently, the increasing prevalence of chronic conditions leading to organ failure serves as a major driver for the continued expansion of pre-transplant compatibility testing. Diseases such as end-stage renal disease and cardiovascular failure are expanding patient waitlists, thereby necessitating rigorous histocompatibility profiling and HLA typing to facilitate successful organ allocation. Data from the Health Resources and Services Administration's OrganDonor.gov, updated in May 2025, indicates that over 103,000 individuals were listed on the national transplant waiting list. This intense clinical demand supports procedural throughput, as evidenced by the Organ Procurement and Transplantation Network's January 2025 report, which noted a record 48,149 organ transplants performed in the United States during 2024, highlighting the ecosystem's reliance on robust diagnostic infrastructure.

Market Challenge

The enduring scarcity of donor organs serves as a primary constraint on the commercial growth of the global organ transplant diagnostics market. Because the use of diagnostic assays is intrinsically linked to the volume of surgical procedures, the limited availability of organs effectively places a hard cap on market revenue potential. This restriction diminishes the frequency of pre-surgical compatibility testing and limits the number of patients who can transition into the post-transplantation monitoring phase. Consequently, the industry is unable to fully meet clinical demand, as the addressable patient population is physically constrained by the stagnant supply of donors.

This structural bottleneck results in a widening disparity between potential demand and actual testing volumes. According to data from the Organ Procurement and Transplantation Network, there were more than 103,000 candidates awaiting a transplant on the national waiting list in the United States in 2024. This significant gap illustrates how the shortage of donors precludes a large portion of the patient population from utilizing the full spectrum of diagnostic services, thereby impeding the generation of recurring revenue streams that would otherwise arise from routine profiling.

Market Trends

The incorporation of Artificial Intelligence (AI) and Machine Learning (ML) is revolutionizing predictive risk stratification, targeting inefficiencies in organ procurement that conventional methods fail to address. These advanced technologies are being utilized to interpret complex donor variables, thereby optimizing the crucial decision-making period between the withdrawal of life support and organ retrieval. By offering accurate predictions of donor progression, AI tools help minimize the discard rate of viable organs, directly mitigating the ongoing supply shortage; for example, The Guardian reported in November 2025 that a machine learning model developed by Stanford University researchers achieved a 60% reduction in futile procurement attempts compared to standard predictions.

In parallel, the market is witnessing a transition toward personalized transplant medicine driven by the adoption of novel RNA-based biomarkers that provide deeper insights than standard liquid biopsies. Clinicians are increasingly relying on transcriptomic profiling to evaluate rejection risks with greater specificity, enabling the customization of immunosuppression regimens to reduce long-term graft toxicity. This shift toward precision diagnostics is reflected in the commercial success of next-generation assays; Verici Dx reported in a July 2025 corporate update that it received 299 orders for its Tutivia diagnostic test in the second quarter of 2025, demonstrating a growing reliance on advanced genomic signatures for individualized patient management.

Key Market Players

• Thermo Fisher Scientific, Inc.
• Illumina, Inc.
• F. Hoffmann La-Roche Ltd
• Abbott
• QIAGEN
• Bruker
• Becton, Dickinson and Company
• Immucor, Inc.
• Bio-Rad Laboratories, Inc.
• Omixon Inc.

Report Scope

In this report, the Global Organ Transplant Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Organ Transplant Diagnostics Market, By Offering

• Kits and Assays
• Consumables
• Services

Organ Transplant Diagnostics Market, By Application

• Donor Testing
  • (Pre-transplantation testing (Histocompatibility Testing, Blood Profiling Testing, Other Testing))
• Post-transplantation testing
  • (Post-Infection Testing, Risk of Disorder Testing, Other Testing)
• Recipient Testing
  • (Pre-transplantation testing, Histocompatibility Testing, Blood Profiling Testing, Other Testing)
• Post-transplantation Testing
  • (Post-Infection Testing, Risk of Disorder Testing, Other Testing)

Organ Transplant Diagnostics Market, By Transplant Type

• Solid Organ Transplant (Kidney, Liver, Lung, Pancreas, Other Organs Transplant)
• Stem Cell Transplant

Organ Transplant Diagnostics Market, By Technology

• Molecular Technologies (PCR, Sanger Sequencing, Next-Generation Sequencing (NGS), Other Molecular Technologies)
• Non-molecular Technologies (Serology, Flow Cytometry)
• Other Technologies

Organ Transplant Diagnostics Market, By End User

• Hospitals and Transplant Centers
• Academic and Research Institutions
• Reference Laboratories
• Other End Users

Organ Transplant Diagnostics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Organ Transplant Diagnostics Market.

Available Customizations:

Global Organ Transplant Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Organ Transplant Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Offering (Kits and Assays, Consumables, Services)
  • 5.2.2. By Application (Donor Testing (Pre-transplantation testing (Histocompatibility Testing, Blood Profiling Testing, Other Testing), Post-transplantation testing (Post-Infection Testing, Risk of Disorder Testing, Other Testing)), Recipient Testing (Pre-transplantation testing (Histocompatibility Testing, Blood Profiling Testing, Other Testing), Post-transplantation Testing (Post-Infection Testing, Risk of Disorder Testing,, Other Testing)))
  • 5.2.3. By Transplant Type (Solid Organ Transplant (Kidney, Liver, Lung, Pancreas, Other Organs Transplant), Stem Cell Transplant)
  • 5.2.4. By Technology (Molecular Technologies (PCR, Sanger Sequencing, Next-Generation Sequencing (NGS), Other Molecular Technologies), Non-molecular Technologies (Serology, Flow Cytometry), Other Technologies)
  • 5.2.5. By End User (Hospitals and Transplant Centers, Academic and Research Institutions, Reference Laboratories, Other End Users)
  • 5.2.6. By Region
  • 5.2.7. By Company (2025)
• 5.3. Market Map

6. North America Organ Transplant Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Offering
  • 6.2.2. By Application
  • 6.2.3. By Transplant Type
  • 6.2.4. By Technology
  • 6.2.5. By End User
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Organ Transplant Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Offering
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By Transplant Type
      • 6.3.1.2.4. By Technology
      • 6.3.1.2.5. By End User
  • 6.3.2. Canada Organ Transplant Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Offering
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By Transplant Type
      • 6.3.2.2.4. By Technology
      • 6.3.2.2.5. By End User
  • 6.3.3. Mexico Organ Transplant Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Offering
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By Transplant Type
      • 6.3.3.2.4. By Technology
      • 6.3.3.2.5. By End User

7. Europe Organ Transplant Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Offering
  • 7.2.2. By Application
  • 7.2.3. By Transplant Type
  • 7.2.4. By Technology
  • 7.2.5. By End User
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Organ Transplant Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Offering
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By Transplant Type
      • 7.3.1.2.4. By Technology
      • 7.3.1.2.5. By End User
  • 7.3.2. France Organ Transplant Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Offering
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By Transplant Type
      • 7.3.2.2.4. By Technology
      • 7.3.2.2.5. By End User
  • 7.3.3. United Kingdom Organ Transplant Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Offering
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By Transplant Type
      • 7.3.3.2.4. By Technology
      • 7.3.3.2.5. By End User
  • 7.3.4. Italy Organ Transplant Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Offering
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By Transplant Type
      • 7.3.4.2.4. By Technology
      • 7.3.4.2.5. By End User
  • 7.3.5. Spain Organ Transplant Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Offering
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By Transplant Type
      • 7.3.5.2.4. By Technology
      • 7.3.5.2.5. By End User

8. Asia Pacific Organ Transplant Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Offering
  • 8.2.2. By Application
  • 8.2.3. By Transplant Type
  • 8.2.4. By Technology
  • 8.2.5. By End User
  • 8.2.6. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Organ Transplant Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Offering
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By Transplant Type
      • 8.3.1.2.4. By Technology
      • 8.3.1.2.5. By End User
  • 8.3.2. India Organ Transplant Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Offering
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By Transplant Type
      • 8.3.2.2.4. By Technology
      • 8.3.2.2.5. By End User
  • 8.3.3. Japan Organ Transplant Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Offering
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By Transplant Type
      • 8.3.3.2.4. By Technology
      • 8.3.3.2.5. By End User
  • 8.3.4. South Korea Organ Transplant Diagnostics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Offering
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By Transplant Type
      • 8.3.4.2.4. By Technology
      • 8.3.4.2.5. By End User
  • 8.3.5. Australia Organ Transplant Diagnostics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Offering
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By Transplant Type
      • 8.3.5.2.4. By Technology
      • 8.3.5.2.5. By End User

9. Middle East & Africa Organ Transplant Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Offering
  • 9.2.2. By Application
  • 9.2.3. By Transplant Type
  • 9.2.4. By Technology
  • 9.2.5. By End User
  • 9.2.6. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Organ Transplant Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Offering
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By Transplant Type
      • 9.3.1.2.4. By Technology
      • 9.3.1.2.5. By End User
  • 9.3.2. UAE Organ Transplant Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Offering
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By Transplant Type
      • 9.3.2.2.4. By Technology
      • 9.3.2.2.5. By End User
  • 9.3.3. South Africa Organ Transplant Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Offering
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By Transplant Type
      • 9.3.3.2.4. By Technology
      • 9.3.3.2.5. By End User

10. South America Organ Transplant Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Offering
  • 10.2.2. By Application
  • 10.2.3. By Transplant Type
  • 10.2.4. By Technology
  • 10.2.5. By End User
  • 10.2.6. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Organ Transplant Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Offering
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By Transplant Type
      • 10.3.1.2.4. By Technology
      • 10.3.1.2.5. By End User
  • 10.3.2. Colombia Organ Transplant Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Offering
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By Transplant Type
      • 10.3.2.2.4. By Technology
      • 10.3.2.2.5. By End User
  • 10.3.3. Argentina Organ Transplant Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Offering
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By Transplant Type
      • 10.3.3.2.4. By Technology
      • 10.3.3.2.5. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Organ Transplant Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Thermo Fisher Scientific, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Illumina, Inc.
• 15.3. F. Hoffmann La-Roche Ltd
• 15.4. Abbott
• 15.5. QIAGEN
• 15.6. Bruker
• 15.7. Becton, Dickinson and Company
• 15.8. Immucor, Inc.
• 15.9. Bio-Rad Laboratories, Inc.
• 15.10. Omixon Inc.

16. Strategic Recommendations

17. About Us & Disclaimer